Naunyn Schmiedebergs Arch Pharmacol
Naunyn-Schmiedeberg's Archives of Pharmacology
0028-1298
1432-1912
Springer-Verlag
Berlin/Heidelberg


1705472
17075718
107
10.1007/s00210-006-0107-9
Review


Why are mineralocorticoid receptor antagonists cardioprotective?

Chai
Wenxia



Danser
A. H. Jan

+31-10-4087540
+31-10-4089458
a.danser@erasmusmc.nl



Department of Pharmacology, Room EE1418b, Erasmus MC, Dr. Molewaterplein 50, 3015 GE Rotterdam, The Netherlands 

31
10
2006

12
2006

374
3
153
162
11
7
2006

29
8
2006


© Springer-Verlag 2006

Two clinical trials, the Randomized ALdosterone Evaluation Study (RALES) and the EPlerenone HEart failure and SUrvival Study (EPHESUS), have recently shown that mineralocorticoid receptor (MR) antagonists reduce mortality in patients with heart failure on top of ACE inhibition. This effect could not be attributed solely to blockade of the renal MR-mediated effects on blood pressure, and it has therefore been proposed that aldosterone, the endogenous MR agonist, also acts extrarenally, in particular in the heart. Indeed, MR are present in cardiac tissue, and possibly aldosterone synthesis occurs in the heart. This review critically addresses the following questions: (1) is aldosterone synthesized at cardiac tissue sites, (2) what agonist stimulates cardiac MR normally, and (3) what effects are mediated by aldosterone/MR in the heart that could explain the beneficial effects of MR blockade in heart failure? Conclusions are that most, if not all, of cardiac aldosterone originates in the circulation (i.e., is of adrenal origin), and that glucocorticoids, in addition to aldosterone, may serve as the endogenous agonist of cardiac MR. MR-mediated effects in the heart include effects on endothelial function, cardiac fibrosis and hypertrophy, oxidative stress, cardiac inotropy, coronary flow, and arrhythmias. Some of these effects occur via or in synergy with angiotensin II, and involve a non-MR-mediated mechanism. This raises the possibility that aldosterone synthase inhibitors might exert beneficial effects on top of MR blockade.

Keywords
Aldosterone
Mineralocorticoid receptor
Cortisol
Non-genomic
Inotropy
Arrhythmia

issue-copyright-statement
© Springer-Verlag 2006




Introduction
1
1
2
1
Fig. 1
1
2
1
1
2
1
 receptor activation also results in MR stimulation in an aldosterone-independent manner




2003
2003
1994
1998
1
2
2004
2000
2000
).
2002
2002
).
1999
2003
1999
2003
), and it is now generally assumed that aldosterone also acts extrarenally, in agreement with the concept of local RAAS.
1995
2001
1998
1997
), these data suggest that aldosterone, like Ang II, may be formed and act locally in the heart. This review addresses the following questions: (1) is aldosterone really synthesized at cardiac tissue sites, (2) what agonist stimulates cardiac MR, and (3) what effects are mediated by aldosterone/MR in the heart that could explain the beneficial effects of MR blockade in heart failure?

Aldosterone synthesis at cardiac tissue sites?
CYP11B2
, ‘aldosterone synthase’). Aldosterone synthesis in the adrenal cortex is regulated by Ang II, potassium and, more weakly, sodium and adrenocorticotrophic hormone.
1998
1997
1995
1997
2003
1998
2004
2001
2004
2003
1994
1997
2001
2005
2004
1998
). Furthermore, the cardiac levels correlated closely with the plasma levels of aldosterone, and they decreased to levels at or below the detection limit after adrenalectomy.
2006
2
1994
1997
2001
2005
2000
2006
2005
2004
Fig. 2
2006
)





Activation of cardiac mineralocorticoid receptors by aldosterone?
+
2000
1995
1992
2005
2004
1992
).
d
1987
1994
3
2000
3
1994
Fig. 3
top
bottom
1987
2005
1994
). Note that, in the absence of 11βHSD2, MR bind cortisol with an affinity equal to that for aldosterone




2006
2005b
2004
2006
2005b
3
2002
2003
2000
2005b
2006
2006
).

Genomic versus non-genomic effects
+
 channel) after several hours. Genomic effects can be inhibited by agents that block either transcription (e.g., actinomycin D) or translation (e.g., cycloheximide).
2002
2003
2004
2005
2004
2003
2005a
1995
2005a
2005
2005a
+
2003
2001
). Thus, to solve this issue, future studies should make use of alternative MR antagonists such as eplerenone. Eplerenone displays increased selectivity for the MR over other steroid receptors, although its affinity for the MR in vitro is 10- to 20-fold lower than that of spironolactone.
3
2+
+
+
2004b
2005a
2003
2002
2004
1997
+
+
+
+
+
+
2004
2005
2004
).

Effects of aldosterone in the cardiovascular system
2005
2005
1995
), albeit at low levels, supports the concept that these organs possess the cellular machinery required for direct aldosterone action, irrespective of the source of aldosterone.
Endothelial dysfunction
2005
2004
2004
2004
).

Oxidative stress, inflammation, fibrosis and atherosclerosis
2005
2003
2002
2002
2005
2004
2004
2002
1994
2005
2005
2006
) fed a high-cholesterol diet, most likely by attenuating oxidative stress and inflammation.

Cardiac inotropy and coronary flow
2005a
1996
2002
2002
2005a
2002
2005a
), and thus it appears that the effects of aldosterone on inotropy and flow occur in a non-MR-mediated manner.
4
2005b
2005b
4
2002
2004b
2005a
2004
2003
+
+
2004
2000
Fig. 4
Left panel
Right panel
2005b
)




2005b
2005
2004
3
+
+
+
+
2005
2003
2004
2003
2003
), needs to be addressed.

Arrhythmias
1999
2003
2005
2001
2001
).
2005a
2006
5
2006
2004
2005b
2006
2006
2005
2005a
2006
Fig. 5
left panel
middle panel
right panel
A
S
E
A + E). 
2005a
2006
P
 < 0.05 versus control





Cardiac hypertrophy
1997
CYP11B2
2004a
1998
1998
1999
2004
2004
2005c
2005
CYP11B2
CYP11B1
2005
2005
CYP11B1
2005
2005
), should address this possibility.

Interaction with angiotensin II
2005
2002
2005
2004
2004
1
2005a
1987
1996
2005
).


Clinical perspective: why are MR antagonists cardioprotective?
The beneficial effects of MR antagonists in heart failure cannot be explained on the basis of their renal and/or blood pressure-lowering effects. Most likely they relate, at least in part, to blockade of a wide range of MR-mediated effects in the heart, including endothelial dysfunction, a decrease in cardiac inotropy and coronary flow, and the induction of fibrosis, hypertrophy, oxidative stress and arrhythmias. Some of these effects occur via or in synergy with Ang II. Given the virtual absence of aldosterone production in the heart, and in view of the low cardiac levels of the cortisol-inactivating enzyme 11β-HSD2, it is unlikely that, under all conditions, aldosterone is the endogenous agonist of cardiac MR. Thus, some of the MR-mediated effects in the heart may be due to MR activation by glucocorticoids, particularly when ROS levels are high. The aldosterone levels in the failing human heart, but not those in the healthy heart, are high enough to be of functional importance. Whether some of the above (acute, ‘non-genomic’) in vitro effects of aldosterone are mediated via a non-MR-mediated mechanism remains to be proven, in particular because no (membrane receptor) candidate has been identified so far that induces these effects. If true, however, aldosterone synthase inhibitors might be expected to exert beneficial effects on top of MR blockade.


References
Abiose
AK

Mansoor
GA

Barry
M

Soucier
R

Nair
CK

Hager
D


Effect of spironolactone on endothelial function in patients with congestive heart failure on conventional medical therapy
Am J Cardiol
2004
93
1564
1566
10.1016/j.amjcard.2004.03.015

15194040


Ahokas
RA

Sun
Y

Bhattacharya
SK

Gerling
IC

Weber
KT


Aldosteronism and a proinflammatory vascular phenotype: role of Mg2+, Ca2+, and H2O2 in peripheral blood mononuclear cells
Circulation
2005
111
51
57
10.1161/01.CIR.0000151516.84238.37

15611366


Alzamora
R

Michea
L

Marusic
ET


Role of 11beta-hydroxysteroid dehydrogenase in nongenomic aldosterone effects in human arteries
Hypertension
2000
35
1099
1104

10818071


Arriza
JL

Weinberger
C

Cerelli
G

Glaser
TM

Handelin
BL

Housman
DE

Evans
RM


Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor
Science
1987
237
268
275
10.1126/science.3037703

3037703


Barbato
A

Russo
P

Siani
A

Folkerd
EJ

Miller
MA

Venezia
A

Grimaldi
C

Strazzullo
P

Cappuccio
FP


Aldosterone synthase gene (CYP11B2) C-344T polymorphism, plasma aldosterone, renin activity and blood pressure in a multi-ethnic population
J Hypertens
2004
22
1895
1901
10.1097/00004872-200410000-00011

15361760


Barbato
JC

Mulrow
PJ

Shapiro
JI

Franco-Saenz
R


Rapid effects of aldosterone and spironolactone in the isolated working rat heart
Hypertension
2002
40
130
135
10.1161/01.HYP.0000025879.29822.24

12154102


Barbato
JC

Rashid
S

Mulrow
PJ

Shapiro
JI

Franco-Saenz
R


Mechanisms for aldosterone and spironolactone-induced positive inotropic actions in the rat heart
Hypertension
2004
44
751
757
10.1161/01.HYP.0000144466.11568.7e

15466666


Batenburg
WW

Garrelds
IM

Bernasconi
CC

Juillerat-Jeanneret
L

Kats
JP

Saxena
PR

Danser
AHJ


Angiotensin II type 2 receptor-mediated vasodilation in human coronary microarteries
Circulation
2004
109
2296
2301
10.1161/01.CIR.0000128696.12245.57

15117835


Beck
L

Blanc-Guillemaud
V

Cherif
OK

Jover
B

Davy
JM


Effects of spironolactone and fosinopril on the spontaneous and chronic ventricular arrhythmias in a rat model of myocardial infarction
Cardiology
2001
96
85
93
10.1159/000049089

11740137


Blasi
ER

Rocha
R

Rudolph
AE

Blomme
EA

Polly
ML

McMahon
EG


Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats
Kidney Int
2003
63
1791
1800
10.1046/j.1523-1755.2003.00929.x

12675855


Brand
E

Chatelain
N

Mulatero
P

Fery
I

Curnow
K

Jeunemaitre
X

Corvol
P

Pascoe
L

Soubrier
F


Structural analysis and evaluation of the aldosterone synthase gene in hypertension
Hypertension
1998
32
198
204

9719043


Brilla
CG

Zhou
G

Matsubara
L

Weber
KT


Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone
J Mol Cell Cardiol
1994
26
809
820
10.1006/jmcc.1994.1098

7966349


Caballero
R

Moreno
I

Gonzalez
T

Arias
C

Valenzuela
C

Delpon
E

Tamargo
J


Spironolactone and its main metabolite, canrenoic acid, block human ether-a-go-go-related gene channels
Circulation
2003
107
889
895
10.1161/01.CIR.0000048189.58449.F7

12591761


Calo
LA

Zaghetto
F

Pagnin
E

Davis
PA

Mozzi
P

Sartorato
P

Martire
G

Fiore
C

Armanini
D


Effect of aldosterone and glycyrrhetinic acid on the protein expression of PAI-1 and p22(phox) in human mononuclear leukocytes
J Clin Endocrinol Metab
2004
89
1973
1976
10.1210/jc.2003-031545

15070972


Cargnelli
G

Trevisi
L

Debetto
P

Luciani
S

Bova
S


Effects of canrenone on aorta and right ventricle of the rat
J Cardiovasc Pharmacol
2001
37
540
547
10.1097/00005344-200105000-00006

11336105


Casal
AJ

Silvestre
JS

Delcayre
C

Capponi
AM


Expression and modulation of steroidogenic acute regulatory protein messenger ribonucleic acid in rat cardiocytes and after myocardial infarction
Endocrinology
2003
144
1861
1868
10.1210/en.2002-220943

12697693


Chai
W

Garrelds
IM

Arulmani
U

Schoemaker
RG

Lamers
JMJ

Danser
AHJ


Genomic and non-genomic effects of aldosterone in the rat heart: why is spironolactone cardioprotective?
Br J Pharmacol
2005
145
664
671
10.1038/sj.bjp.0706220

15834444


Chai
W

Garrelds
IM

Vries
R

Batenburg
WW

Kats
JP

Danser
AHJ


Nongenomic effects of aldosterone in the human heart. Interaction with Angiotensin II
Hypertension
2005
46
701
706
10.1161/01.HYP.0000182661.98259.4f

16144984


Chai
W

Schaik
RHN

Fessem
MA

Kofflard
MJM

Cate
FJ

Danser
AHJ


Aldosterone and cardiac hypertrophy in subjects with hypertrophic cardiomyopathy
Circulation
2005
112
suppl II
356

Chai W, van Schaik RHN, van Fessem MA, Kofflard MJM, ten Cate FJ, Danser AHJ (2005c) Aldosterone and cardiac hypertrophy in subjects with hypertrophic cardiomyopathy. Circulation 112 (suppl II):356 (Abstract) 

Chai
W

Garrelds
IM

Vries
R

Danser
AHJ


Cardioprotective effects of eplerenone in the rat heart: interaction with locally synthesized or blood-derived aldosterone?
Hypertension
2006
47
665
670
10.1161/01.HYP.0000205831.39339.a5

16490840


Danser
AHJ


Local renin-angiotensin systems: the unanswered questions
Int J Biochem Cell Biol
2003
35
759
768
10.1016/S1357-2725(02)00178-4

12676161


Danser
AHJ

Kats
JP

Admiraal
PJJ

Derkx
FHM

Lamers
JMJ

Verdouw
PD

Saxena
PR

Schalekamp
MADH


Cardiac renin and angiotensins. Uptake from plasma versus in situ synthesis
Hypertension
1994
24
37
48

8021006


Danser
AHJ

Kesteren
CAM

Bax
WA

Tavenier
M

Derkx
FHM

Saxena
PR

Schalekamp
MADH


Prorenin, renin, angiotensinogen, and angiotensin-converting enzyme in normal and failing human hearts. Evidence for renin binding
Circulation
1997
96
220
226

9236437


Kloet
ER

Acker
SA

Sibug
RM

Oitzl
MS

Meijer
OC

Rahmouni
K

Jong
W


Brain mineralocorticoid receptors and centrally regulated functions
Kidney Int
2000
57
1329
1336
10.1046/j.1523-1755.2000.00971.x

10760063


Lannoy
LM

Danser
AHJ

Kats
JP

Schoemaker
RG

Saxena
PR

Schalekamp
MADH


Renin-angiotensin system components in the interstitial fluid of the isolated perfused rat heart. Local production of angiotensin I
Hypertension
1997
29
1240
1251

9180624


Farquharson
CA

Struthers
AD


Gradual reactivation over time of vascular tissue angiotensin I to angiotensin II conversion during chronic lisinopril therapy in chronic heart failure
J Am Coll Cardiol
2002
39
767
775
10.1016/S0735-1097(02)01689-3

11869839


Fiebeler
A

Nussberger
J

Shagdarsuren
E

Rong
S

Hilfenhaus
G

Al-Saadi
N

Dechend
R

Wellner
M

Meiners
S

Maser-Gluth
C

Jeng
AY

Webb
RL

Luft
FC

Müller
DN


Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage
Circulation
2005
111
3087
3094
10.1161/CIRCULATIONAHA.104.521625

15939810


Fujita
M

Minamino
T

Asanuma
H

Sanada
S

Hirata
A

Wakeno
M

Myoishi
M

Okuda
H

Ogai
A

Okada
K

Tsukamoto
O

Koyama
H

Hori
M

Kitakaze
M


Aldosterone nongenomically worsens ischemia via protein kinase C-dependent pathways in hypoperfused canine hearts
Hypertension
2005
46
113
117
10.1161/01.HYP.0000171184.84077.80

15956114


Funder
JW


The nongenomic actions of aldosterone
Endocr Rev
2005
26
313
321
10.1210/er.2005-0004

15814845


Funder
JW


RALES, EPHESUS and redox
J Steroid Biochem Mol Biol
2005
93
121
125
10.1016/j.jsbmb.2004.12.010

15860254


Ganapathipillai
S

Laval
G

Hoffmann
IS

Castejon
AM

Nicod
J

Dick
B

Frey
FJ

Frey
BM

Cubeddu
LX

Ferrari
P


CYP11B2-CYP11B1 haplotypes associated with decreased 11 beta-hydroxylase activity
J Clin Endocrinol Metab
2005
90
1220
1225
10.1210/jc.2004-1031

15507509


Glorioso
N

Filigheddu
F

Parpaglia
PP

Soro
A

Troffa
C

Argiolas
G

Mulatero
P


11beta-Hydroxysteroid dehydrogenase type 2 activity is associated with left ventricular mass in essential hypertension
Eur Heart J
2005
26
498
504
10.1093/eurheartj/ehi070

15618035


Gomez-Sanchez
CE

Zhou
MY

Cozza
EN

Morita
H

Foecking
MF

Gomez-Sanchez
EP


Aldosterone biosynthesis in the rat brain
Endocrinology
1997
138
3369
3373
10.1210/en.138.8.3369

9231789


Gomez-Sanchez
EP

Ahmad
N

Romero
DG

Gomez-Sanchez
CE


Origin of aldosterone in the rat heart
Endocrinology
2004
145
4796
4802
10.1210/en.2004-0295

15308609


Gonzalez
M

Lobos
L

Castillo
F

Galleguillos
L

Lopez
NC

Michea
L


High-salt diet inhibits expression of angiotensin type 2 receptor in resistance arteries
Hypertension
2005
45
853
859
10.1161/01.HYP.0000161990.98383.ad

15809360


Good
DW

George
T

Watts
BA


Aldosterone inhibits HCO absorption via a nongenomic pathway in medullary thick ascending limb
Am J Physiol Renal Physiol
2002
283
F699
706

12217861


Hagendorf
A

Koper
JW

Jong
FH

Brinkmann
AO

Lamberts
SWJ

Feelders
RA


Expression of the human glucocorticoid receptor splice variants alpha, beta, and P in peripheral blood mononuclear leukocytes in healthy controls and in patients with hyper- and hypocortisolism
J Clin Endocrinol Metab
2005
90
6237
6243
10.1210/jc.2005-1042

16118334


Hautanena
A

Lankinen
L

Kupari
M

Janne
OA

Adlercreutz
H

Nikkila
H

White
PC


Associations between aldosterone synthase gene polymorphism and the adrenocortical function in males
J Intern Med
1998
244
11
18
10.1046/j.1365-2796.1998.00308.x

9698019


Hayashi
M

Tsutamoto
T

Wada
A

Tsutsui
T

Ishii
C

Ohno
K

Fujii
M

Taniguchi
A

Hamatani
T

Nozato
Y

Kataoka
K

Morigami
N

Ohnishi
M

Kinoshita
M

Horie
M


Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction
Circulation
2003
107
2559
2565
10.1161/01.CIR.0000068340.96506.0F

12732605


Hilgers
KF

Schmidt
BM


Gene variants of aldosterone synthase and hypertension
J Hypertens
2005
23
1957
1959
10.1097/01.hjh.0000186833.79243.67

16208133


Jaffe
IZ

Mendelsohn
ME


Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells
Circ Res
2005
96
643
650
10.1161/01.RES.0000159937.05502.d1

15718497


Jorde
UP

Vittorio
T

Katz
SD

Colombo
PC

Latif
F

Jemtel
TH


Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure
Circulation
2002
106
1055
1057
10.1161/01.CIR.0000030935.89559.04

12196328


Keavney
B

Mayosi
B

Gaukrodger
N

Imrie
H

Baker
M

Fraser
R

Ingram
M

Watkins
H

Farrall
M

Davies
E

Connell
J


Genetic variation at the locus encompassing 11-beta hydroxylase and aldosterone synthase accounts for heritability in cortisol precursor (11-deoxycortisol) urinary metabolite excretion
J Clin Endocrinol Metab
2005
90
1072
1077
10.1210/jc.2004-0870

15522937


Liu
SL

Schmuck
S

Chorazcyzewski
JZ

Gros
R

Feldman
RD


Aldosterone regulates vascular reactivity: short-term effects mediated by phosphatidylinositol 3-kinase-dependent nitric oxide synthase activation
Circulation
2003
108
2400
2406
10.1161/01.CIR.0000093188.53554.44

14557368


Lombès
M

Oblin
ME

Gasc
JM

Baulieu
EE

Farman
N

Bonvalet
JP


Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor
Circ Res
1992
71
503
510

1323429


Lombès
M

Kenouch
S

Souque
A

Farman
N

Rafestin-Oblin
ME


The mineralocorticoid receptor discriminates aldosterone from glucocorticoids independently of the 11 beta-hydroxysteroid dehydrogenase
Endocrinology
1994
135
834
840
10.1210/en.135.3.834

8070376


Lombès
M

Alfaidy
N

Eugene
E

Lessana
A

Farman
N

Bonvalet
JP


Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart
Circulation
1995
92
175
182

7600648


Lösel
R

Feuring
M

Wehling
M


Non-genomic aldosterone action: from the cell membrane to human physiology
J Steroid Biochem Mol Biol
2002
83
167
171
10.1016/S0960-0760(02)00250-9

12650713


Macdonald
JE

Kennedy
N

Struthers
AD


Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment
Heart
2004
90
765
770
10.1136/hrt.2003.017368

15201246


Mazak
I

Fiebeler
A

Müller
DN

Park
JK

Shagdarsuren
E

Lindschau
C

Dechend
R

Viedt
C

Pilz
B

Haller
H

Luft
FC


Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells
Circulation
2004
109
2792
2800
10.1161/01.CIR.0000131860.80444.AB

15159288


Michea
L

Delpiano
AM

Hitschfeld
C

Lobos
L

Lavandero
S

Marusic
ET


Eplerenone blocks nongenomic effects of aldosterone on the Na+/H+ exchanger, intracellular Ca2+ levels, and vasoconstriction in mesenteric resistance vessels
Endocrinology
2005
146
973
980
10.1210/en.2004-1130

15550504


Mihailidou
AS

Mardini
M

Funder
JW


Rapid, nongenomic effects of aldosterone in the heart mediated by epsilon protein kinase C
Endocrinology
2004
145
773
780
10.1210/en.2003-1137

14605011


Moreau
D

Chardigny
JM

Rochette
L


Effects of aldosterone and spironolactone on the isolated perfused rat heart
Pharmacology
1996
53
28
36

8875599


Nagata
K

Obata
K

Xu
J

Ichihara
S

Noda
A

Kimata
H

Kato
T

Izawa
H

Murohara
T

Yokota
M


Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats
Hypertension
2006
47
656
664
10.1161/01.HYP.0000203772.78696.67

16505208


Nakamura
S

Yoshimura
M

Nakayama
M

Ito
T

Mizuno
Y

Harada
E

Sakamoto
T

Saito
Y

Nakao
K

Yasue
H

Ogawa
H


Possible association of heart failure status with synthetic balance between aldosterone and dehydroepiandrosterone in human heart
Circulation
2004
110
1787
1793
10.1161/01.CIR.0000143072.36782.51

15364798


Oberleithner
H


Aldosterone makes human endothelium stiff and vulnerable
Kidney Int
2005
67
1680
1682
10.1111/j.1523-1755.2005.00263.x

15840012


Oberleithner
H

Ludwig
T

Riethmuller
C

Hillebrand
U

Albermann
L

Schafer
C

Shahin
V

Schillers
H


Human endothelium: target for aldosterone
Hypertension
2004
43
952
956
10.1161/01.HYP.0000123572.45556.a5

14993200


Ouvrard-Pascaud
A

Sainte-Marie
Y

Benitah
JP

Perrier
R

Soukaseum
C

Cat
AN

Royer
A

Quang
K

Charpentier
F

Demolombe
S

Mechta-Grigoriou
F

Beggah
AT

Maison-Blanche
P

Oblin
ME

Delcayre
C

Fishman
GI

Farman
N

Escoubet
B

Jaisser
F


Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias
Circulation
2005
111
3025
3033
10.1161/CIRCULATIONAHA.104.503706

15939817


Pitt
B

Zannad
F

Remme
WJ

Cody
R

Castaigne
A

Perez
A

Palensky
J

Wittes
J


The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators
N Engl J Med
1999
341
709
717
10.1056/NEJM199909023411001

10471456


Pitt
B

Remme
W

Zannad
F

Neaton
J

Martinez
F

Roniker
B

Bittman
R

Hurley
S

Kleiman
J

Gatlin
M


Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction
N Engl J Med
2003
348
1309
1321
10.1056/NEJMoa030207

12668699


Qin
W

Rudolph
AE

Bond
BR

Rocha
R

Blomme
EA

Goellner
JJ

Funder
JW

McMahon
EG


Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure
Circ Res
2003
93
69
76
10.1161/01.RES.0000080521.15238.E5

12791709


Saris
JJ

Derkx
FHM

Bruin
RJA

Dekkers
DHW

Lamers
JMJ

Saxena
PR

Schalekamp
MADH

Danser
AHJ


High-affinity prorenin binding to cardiac man-6-P/IGF-II receptors precedes proteolytic activation to renin
Am J Physiol
2001
280
H1706
H1715

Saris JJ, Derkx FHM, de Bruin RJA, Dekkers DHW, Lamers JMJ, Saxena PR, Schalekamp MADH, Danser AHJ (2001) High-affinity prorenin binding to cardiac man-6-P/IGF-II receptors precedes proteolytic activation to renin. Am J Physiol 280:H1706–H1715 

Sato
A

Funder
JW


High glucose stimulates aldosterone-induced hypertrophy via type I mineralocorticoid receptors in neonatal rat cardiomyocytes
Endocrinology
1996
137
4145
4153
10.1210/en.137.10.4145

8828470


Sato
A

Liu
JP

Funder
JW


Aldosterone rapidly represses protein kinase C activity in neonatal rat cardiomyocytes in vitro
Endocrinology
1997
138
3410
3416
10.1210/en.138.8.3410

9231795


Schmidt
BMW

Oehmer
S

Delles
C

Bratke
R

Schneider
MP

Klingbeil
A

Fleischmann
EH

Schmieder
RE


Rapid nongenomic effects of aldosterone on human forearm vasculature
Hypertension
2003
42
156
160
10.1161/01.HYP.0000083298.23119.16

12860833


Schunkert
H

Hense
HW

Muscholl
M

Luchner
A

Kürzinger
S

Danser
AHJ

Riegger
GA


Associations between circulating components of the renin-angiotensin-aldosterone system and left ventricular mass
Heart
1997
77
24
31

9038690


Schunkert
H

Hengstenberg
C

Holmer
SR

Broeckel
U

Luchner
A

Muscholl
MW

Kurzinger
S

Doring
A

Hense
HW

Riegger
GA


Lack of association between a polymorphism of the aldosterone synthase gene and left ventricular structure
Circulation
1999
99
2255
2260

10226090


Silvestre
JS

Robert
V

Heymes
C

Aupetit-Faisant
B

Mouas
C

Moalic
JM

Swynghedauw
B

Delcayre
C


Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation
J Biol Chem
1998
273
4883
4891
10.1074/jbc.273.9.4883

9478930


Stella
P

Bigatti
G

Tizzoni
L

Barlassina
C

Lanzani
C

Bianchi
G

Cusi
D


Association between aldosterone synthase (CYP11B2) polymorphism and left ventricular mass in human essential hypertension
J Am Coll Cardiol
2004
43
265
270
10.1016/j.jacc.2003.08.034

14736447


Sun
Y

Zhang
J

Lu
L

Chen
SS

Quinn
MT

Weber
KT


Aldosterone-induced inflammation in the rat heart: role of oxidative stress
Am J Pathol
2002
161
1773
1781

12414524


Suzuki
J

Iwai
M

Mogi
M

Oshita
A

Yoshii
T

Higaki
J

Horiuchi
M


Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation
Arterioscler Thromb Vasc Biol
2006
26
917
921
10.1161/01.ATV.0000204635.75748.0f

16424347


Takai
S

Jin
D

Muramatsu
M

Kirimura
K

Sakonjo
H

Miyazaki
M


Eplerenone inhibits atherosclerosis in nonhuman primates
Hypertension
2005
46
1135
1139
10.1161/01.HYP.0000184640.81730.22

16203870


Takeda
Y

Miyamori
I

Yoneda
T

Iki
K

Hatakeyama
H

Blair
IA

Hsieh
FY

Takeda
R


Production of aldosterone in isolated rat blood vessels
Hypertension
1995
25
170
173

7843766


Takeda
Y

Miyamori
I

Inaba
S

Furukawa
K

Hatakeyama
H

Yoneda
T

Mabuchi
H

Takeda
R


Vascular aldosterone in genetically hypertensive rats
Hypertension
1997
29
45
48

9039078


Takeda
Y

Yoneda
T

Demura
M

Miyamori
I

Mabuchi
H


Cardiac aldosterone production in genetically hypertensive rats
Hypertension
2000
36
495
500

11040225


Therien
AG

Blostein
R


Mechanisms of sodium pump regulation
Am J Physiol Cell Physiol
2000
279
C541
566

10942705


Tom
B

Garrelds
IM

Scalbert
E

Stegmann
APA

Boomsma
F

Saxena
PR

Danser
AHJ


ACE-versus chymase-dependent angiotensin II generation in human coronary arteries: a matter of efficiency?
Arterioscler Thromb Vasc Biol
2003
23
251
256
10.1161/01.ATV.0000051875.41849.25

12588767


Tsybouleva
N

Zhang
L

Chen
S

Patel
R

Lutucuta
S

Nemoto
S

DeFreitas
G

Entman
M

Carabello
BA

Roberts
R

Marian
AJ


Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy
Circulation
2004
109
1284
1291
10.1161/01.CIR.0000121426.43044.2B

14993121


Hooft
CS

Sturkenboom
MC

Grootheest
K

Kingma
HJ

Stricker
BH


Adverse drug reaction-related hospitalisations: a nationwide study in The Netherlands
Drug Saf
2006
29
161
168
10.2165/00002018-200629020-00006

16454543


Kats
JP

Danser
AHJ

Meegen
JR

Sassen
LM

Verdouw
PD

Schalekamp
MADH


Angiotensin production by the heart: a quantitative study in pigs with the use of radiolabeled angiotensin infusions
Circulation
1998
98
73
81

9665063


Kats
JP

Duncker
DJ

Haitsma
DB

Schuijt
MP

Niebuur
R

Stubenitsky
R

Boomsma
F

Schalekamp
MADH

Verdouw
PD

Danser
AHJ


Angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade prevent cardiac remodeling in pigs after myocardial infarction: role of tissue angiotensin II
Circulation
2000
102
1556
1563

11004147


Virdis
A

Neves
MF

Amiri
F

Viel
E

Touyz
RM

Schiffrin
EL


Spironolactone improves angiotensin-induced vascular changes and oxidative stress
Hypertension
2002
40
504
510
10.1161/01.HYP.0000034738.79310.06

12364354


Wehling
M


Effects of aldosterone and mineralocorticoid receptor blockade on intracellular electrolytes
Heart Fail Rev
2005
10
39
46
10.1007/s10741-005-2347-z

15947890


Wehling
M

Neylon
CB

Fullerton
M

Bobik
A

Funder
JW


Nongenomic effects of aldosterone on intracellular Ca2+ in vascular smooth muscle cells
Circ Res
1995
76
973
979

7758168


White
PC

Rainey
WE


Editorial: polymorphisms in CYP11B genes and 11-hydroxylase activity
J Clin Endocrinol Metab
2005
90
1252
1255
10.1210/jc.2004-2452

15699546


Xiao
F

Puddefoot
JR

Barker
S

Vinson
GP


Mechanism for aldosterone potentiation of angiotensin II-stimulated rat arterial smooth muscle cell proliferation
Hypertension
2004
44
340
345
10.1161/01.HYP.0000140771.21243.ed

15302841


Yee
KM

Pringle
SD

Struthers
AD


Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure
J Am Coll Cardiol
2001
37
1800
1807
10.1016/S0735-1097(01)01243-8

11401114


Young
MJ

Clyne
CD

Cole
TJ

Funder
JW


Cardiac steroidogenesis in the normal and failing heart
J Clin Endocrinol Metab
2001
86
5121
5126
10.1210/jc.86.11.5121

11701663


Yusuf
S

Sleight
P

Pogue
J

Bosch
J

Davies
R

Dagenais
G


Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators
N Engl J Med
2000
342
145
153
10.1056/NEJM200001203420301

10639539





